natgillin/translations-raw huggingface dataset:
Keep using Xoterna Breezhaler for as long as your doctor tells you.
Zdravljenje z zdravilom Xoterna Breezhaler nadaljujte tako dolgo, kot vam naroči zdravnik.
Keep using your medicine until your doctor tells you to stop.
Zdravilo uporabljajte tako dolgo, dokler vam tako svetuje vaš zdravnik.
Keep using your treatment with Hirobriz Breezhaler for as long as your doctor tells you.
Zdravljenje z zdravilom Hirobriz Breezhaler nadaljujte tako dolgo, kot vam naroči zdravnik.
Keep using your treatment with Onbrez Breezhaler for as long as your doctor tells you.
Zdravljenje z zdravilom Onbrez Breezhaler nadaljujte tako dolgo, kot vam naroči zdravnik.
Keep using your treatment with Oslif Breezhaler for as long as your doctor tells you.
Zdravljenje z zdravilom Oslif Breezhaler nadaljujte tako dolgo, kot vam naroči zdravnik.
Keep vials in the outer carton in order to protect from light.
Vialo shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Keep your cartridge in use at room temperature (15° - 30°C) and discard after 21 days.
Vložek, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi (15 °C - 30 C) in ga po 21 dneh zavrzite.
Keep your cartridge in use at room temperature (15° - 30°C) and discard after 28 days.
Vložek, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi (15 °C - 30 C) in ga po 28 dneh zavrzite.
Keep your child cool especially in hot weather
mora ostati hladen, zlasti ob vročem vremenu;
Keep your doctor informed of your condition and any symptoms before you use or are given Ilaris (see section 2).
Preden prejmete zdravilo Ilaris ali si ga injicirate sami, obvestite zdravnika o svojem zdravstvenem stanju in morebitnih simptomih (glejte poglavje 2).
Keep your fingers away from the needle tip and the safety guard.
Prstov ne približujte niti konici igle niti varnostnemu ščitniku.
Keep your hand away from the plunger.
Roke ne približujte batu.
Keep your head upright
Držite glavo pokonci.
Keep your Humalog 200 units/ml KwikPen in use at room temperature (15° - 30°C) and discard after 28 days.
Zdravilo Humalog 200 enot/ml KwikPen, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi (15 °C - 30 C) in ga po 28 dneh zavrzite.
Keep your Humalog BASAL KwikPen in use at room temperature (15° - 30°C) and discard after 21 days.
Zdravilo Humalog BASAL KwikPen, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi (15 °C - 30 C) in ga po 21 dneh zavrzite.
Keep your Humalog KwikPen in use at room temperature (15° - 30°C) and discard after 28 days.
Zdravilo Humalog KwikPen, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi (15 °C - 30 C) in ga po 28 dneh zavrzite.
Keep your inhaler dry and always make sure your hands are dry before using it.
Pred uporabo si vedno osušite roke.
Keep your inhaler dry and clean.
Inhalator shranjujte na suhem in čistem mestu.
Keep your Liprolog 200 units/ml KwikPen in use at room temperature (15° - 30°C) and discard after 28 days.
Zdravilo Liprolog 200 enot/ml KwikPen, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi (15 °C - 30 C) in ga po 28 dneh zavrzite.
Keep your Liprolog Basal KwikPen in use at room temperature (15° - 30°C) and discard after 21 days.
Zdravilo Liprolog Basal KwikPen, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi (15 °C - 30 C) in ga po 21 dneh zavrzite.
Keep your Liprolog KwikPen in use at room temperature (15° - 30°C) and discard after 28 days.
Zdravilo Liprolog KwikPen, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi (15 °C - 30 C) in ga po 28 dneh zavrzite.
Keep your Lyxumia pens in a safe place out of the reach and sight of children.
Peresnik Lyxumia shranjujte na varnem mestu, nedosegljivo otrokom.
Keep your Lyxumia pens in a safe place out of the reach and sight of children.
Peresnike Lyxumia shranjujte na varnem mestu, nedosegljivo otrokom.
Keep your Pen and Needles out of the sight and reach of children.
Peresnik in igle shranjujte nedosegljive otrokom
Keep your pen at room temperature, below 30°C.
Peresnik shranjujte na sobni temperaturi do 30 °C.
Keep your pen away from dust, dirt and all kinds of liquids.
Hranite ga na čistem mestu, kjer ni prahu, umazanije ali tekočin.
Keep your pen in use at room temperature and away from heat and light.
Vaš peresnik, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi in stran od virov toplote in svetlobe.
Keep your pen out of the reach of others, especially children.
Injekcijski peresnik hranite nedosegljivo drugim osebam, še posebej otrokom.
Keep your syringes and syringe disposal unit out of the sight and reach of children; lock the supplies away if possible.
Brizge in posode za odstranjevanje brizg hranite otrokom skrito in nedosegljivo; če je mogoče, hranite potrebščine zaklenjene.
Keep your syringes and syringe disposal unit out of the sight and reach of children; lock the supplies away if possible.
Brizge in posode za odstranjevanje brizg shranjujte nedosegljivo otrokom; če je mogoče, hranite pribor zaklenjen.
Keep your vial in use in a refrigerator (2°C – 8°C) or at room temperature up to 30°C and discard after 28 days.
Vialo, ki jo trenutno uporabljate, shranjujte v hladilniku (2 °C - 8 °C) ali pri temperaturi do 30 C in jo po 28 dneh zavrzite.
Keep Zinbryta pre-filled syringe and all medicines out of reach and sight of children.
Zdravilo Zinbryta napolnjena injekcijska brizga in vsa zdravila shranjujte nedosegljivo otrokom.
Keep Zoledronic Acid Accord out of the reach and sight of children.
Zdravilo Zoledronska kislina Accord shranjujte nedosegljivo otrokom
Keep Zoledronic acid Actavis out of the sight and reach of children.
Zdravilo Zoledronska kislina Actavis shranjujte nedosegljivo otrokom.
Keep Zoledronic Acid Hospira out of the reach and sight of children.
Zdravilo Zoledronska kislina Hospira shranjujte nedosegljivo otrokom
Keep Zoledronic acid medac out of the sight and reach of children.
Zdravilo Zoledronska kislina medac shranjujte nedosegljivo otrokom
Keep Zoledronic acid Mylan out of the sight and reach of children.
Zdravilo Zoledronska kislina Mylan shranjujte nedosegljivo otrokom
Keep Zoledronic Acid Teva out of the reach and sight of children.
Zdravilo shranjujte nedosegljivo otrokom
Keep Zoledronic acid Teva out of the reach and sight of children.
Zdravilo Zoledronska kislina Teva shranjujte nedosegljivo otrokom
Keep Zometa out of the reach and sight of children.
Zdravilo Zometa shranjujte nedosegljivo otrokom
Keep Zometa out of the reach and sight of children.
Zdravilo Zometa shranjujte nedosegljivo otrokom.
Keeping a diary will help to make sure you do not miss a dose.
Če vodite dnevnik, boste lažje zagotovili, da odmerka ne izpustite.
keeping hands and feet uncovered (no gloves, socks, etc.);
roke in stopala naj bodo nepokriti (brez rokavic, nogavic itd.),
Keeping PecFent safe from children
Shranjevanje zdravila PecFent na varnem pred otroki
Keeping the handset level, place the mouthpiece in the patient’s mouth making sure their lips are closed around it.
Nebulator držite ravno in ustnik vstavite v bolnikova usta; bolnik naj ustnice sklene okoli ustnika.
Keeping the handset level, place the mouthpiece in your mouth and close your lips around it (Figure 3).
Nebulator držite ravno, dajte ustnik v usta in okoli njega zaprite ustnice (slika 3).
Keeping the inhaler tilted downward, put the inhaler to your mouth and make sure you close your lips tightly around the mouth-piece.
Inhalator obdržite v nagnjenem položaju in ga vstavite v usta, nato pa z ustnicami tesno objemite ustnik.
Keeping the needle in the vial, look carefully at the medicine.
Previdno preglejte zdravilo, medtem pa naj igla ostane v viali.
Keeping the needle upwards, press the push-button and the dose selector returns to 0.
Z iglo obrnjeno navzgor pritisnite potisni gumb do konca in izbirnik odmerka se bo vrnil na 0.
Keeping the needle upwards, press the push-button and the dose selector returns to 0.
Z iglo obrnjeno navzgor pritisnite potisni gumb in izbirnik odmerka se bo vrnil na 0.
Keeping the needle upwards, press the push-button and the dose selector returns to 0.
Z iglo obrnjeno navzgor pritisnite potisni gumb in izbirnik odmerka se vrne na vrednost 0.
Keeping the needle upwards, press the push–button all the way in.
Z iglo obrnjeno navzgor pritisnite potisni gumb do konca.
Keeping the needle upwards, press the push–button and the dose selector returns to 0.
Z iglo obrnjeno navzgor pritisnite potisni gumb in izbirnik odmerka se bo vrnil na 0.
Keeping the plunger fully depressed, carefully lift the needle straight out from the injection site.
Medtem ko držite bat pritisnjen do konca, previdno povsem naravnost izvlecite iglo iz vbodnega mesta.
Keeping the push button down, leave the injection needle in place for a few seconds to allow the solution to distribute under the skin, then remove.
Še naprej pritiskajte na gumb in pustite injekcijsko iglo v koži nekaj sekund, da se bo lahko raztopina porazdelila pod kožo, potem iglo potegnite ven.
Keeping the syringe in one hand, use your other hand to gently hold a fold of skin between your thumb and fingers at the previously disinfected injection site.
Brizgo držite v eni roki, z drugo pa kožno gubo na predhodno razkuženem mestu nežno primite med palcem in preostalimi prsti.
Keeping the syringe up, insert the syringe tip into the yellow syringe connector and twist the syringe as indicated by the arrow in the picture until firm.
Držite brizgo pokonci, vstavite konico igle v rumeni konektor za iglo in zasučite brizgo, kot kaže puščica na sliki, dokler ni trdno nameščena.
Keeping the vial on a table, and keeping the vial adapter in the plastic packaging, line up spike on the vial adapter to the centre of the stopper on the vial.
Medtem ko imate vialo na mizi in nastavek za vialo v plastičnem pakiranju, uravnajte konico nastavka za vialo s središčem zamaška na viali.
keletal muscle relaxants (botulinum toxin)
mišični relaksanti (botulinski toksin);
keletally immature (still growing);
osebe z nezrelim okostjem (ki še rastejo);
Kengrexal 50 mg powder for concentrate for solution for injection / infusion cangrelor
Kengrexal 50 mg prašek za koncentrat za raztopino za injiciranje/infundiranje kangrelor
Kengrexal 50 mg powder for concentrate for solution for injection / infusion.
Kengrexal 50 mg prašek za koncentrat za raztopino za injiciranje/infundiranje.
Kengrexal contains cangrelor, a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation in vitro and ex vivo.
Zdravilo Kengrexal vsebuje kangrelor, ki je neposredni antagonist receptorjev P2Y12 na trombocitih, ki in vitro in ex vivo zavira aktivacijo in agregacijo trombocitov, ki jo povzroči adenozin difosfat (ADP).
Kengrexal contains less than 1 mmol sodium (23 mg) per vial, (i.e. essentially “sodium-free”).
Zdravilo Kengrexal vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni 'brez natrija'.
Kengrexal has no influence on the ability to drive and use machines.
Zdravilo Kengrexal nima vpliva na sposobnost vožnje in upravljanja s stroji.
Kengrexal is available in packs of 10.
Zdravilo Kengrexal je na voljo v pakiranjih po 10.
Kengrexal is given to patients who have not been treated before the procedure with other blood-thinning medicines called ‘P2Y12 inhibitors’ (clopidogrel, ticagrelor or prasugrel) taken by mouth, and for whom treatment with these medicines is not possible or desirable.
Zdravilo Kengrexal se uporablja pri bolnikih, ki se pred posegom niso zdravili z drugimi zdravili za redčenje krvi, imenovanimi „zaviralci P2Y12“ (klopidogrel, tikagrelor ali prasugrel), ki se jemljejo peroralno, in pri katerih zdravljenje s temi zdravili ni mogoče ali ni zaželeno.
Kengrexal should not be used during pregnancy.
Zdravila Kengrexal ne smete uporabljati pri nosečnicah.
Kent, CT13 9NJ, United Kingdom.
Kent, CT13 9NJ, Velika Britanija.
Kentera (N=389)
Kentera (n = 389)
Kentera 3.9 mg / 24 hours transdermal patch
Kentera 3,9 mg / 24 ur transdermalni obliž oksibutinin
Kentera 3.9 mg / 24 hours transdermal patch oxybutynin
Kentera 3,9 mg / 24 urni transdermalni obliž oksibutinin
Kentera 90.7 mg/g gel in a metering pump
Kentera 90,7 mg/g gel v odmerni črpalki
Kentera 90.7 mg/g gel in metering pump oxybutynin
Kentera 90,7 mg/g gel v odmerni črpalki oksibutinin
Kentera has a concentration of oxybutynin sufficient to maintain continuous transport over the 3 to 4 day dosing interval.
Koncentracija oksibutinina v obližu Kentera je zadostna za vzdrževanje stalnega prenosa učinkovine med 3- do 4-dnevnimi intervali uporabe.
Kentera is a rapid drying, clear, smooth, odorless, and colorless hydroalcoholic gel that is packaged in a metering pump.
Zdravilo Kentera je hitro sušeči se, bister, gladek, hidroalkoholni gel brez vonja in barve, ki je pakiran v odmerno črpalko.
Kentera is contraindicated in patients with urinary retention, severe gastro-intestinal condition, myasthenia gravis or narrow-angle glaucoma and in patients who are at risk for these conditions.
Zdravilo Kentera je kontraindicirano pri bolnikih z zastojem urina, hudim gastrointestinalnim obolenjem, hudo miastenijo ali ozkokotnim glavkomom ter pri bolnikih, pri katerih obstaja tveganje teh obolenj.
Kentera is not recommended for use in children and adolescents under 18 years old.
Uporaba zdravila Kentera pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
Kentera is packaged in a carton containing 1 metering pump.
Zdravilo Kentera je pakirano v škatlo, ki vsebuje 1 odmerno črpalko.
Kentera oxybutynin
Kentera oksibutinin
Kentera should be used with caution in elderly patients, who may be more sensitive to the effects of centrally acting anticholinergics and exhibit differences in pharmacokinetics.
Pri starejših bolnikih, ki so lahko občutljivejši za učinke antiholinergikov s centralnim delovanjem in pri katerih obstajajo razlike v farmakokinetiki, je treba zdravilo Kentera uporabljati previdno.
Kentera should be used with caution in elderly patients, who may be more sensitive to the effects of centrally acting anticholinergics and exhibit differences in pharmacokinetics.
Pri uporabi obliža Kentera pri starejših bolnikih svetujemo previdnost, saj so lahko bolj občutljivi na učinek centralno delujočega antiholinergika in izkazujejo razlike v farmakokinetiki.
Kentera should be used with caution in patients with hepatic or renal impairment.
Pri bolnikih z jetrno ali ledvično okvaro je treba zdravilo Kentera uporabljati previdno.
Kentera should not be used during pregnancy unless clearly necessary.
Med nosečnostjo ne uporabljajte obližev Kentera, razen če je to nujno potrebno.
Kentera should not be used during pregnancy unless clearly necessary.
Obliža Kentera ne uporabljajte med nosečnostjo, razen če je to nujno potrebno.
Kentera should not to be used during pregnancy unless clearly necessary.
Zdravilo Kentera se ne sme uporabljati med nosečnostjo, razen če je nujno.
Kepivance 6.25 mg powder for solution for injection
Kepivance 6,25 mg prašek za raztopino za injiciranje
Kepivance 6.25 mg powder for solution for injection palifermin
Kepivance 6,25 mg prašek za raztopino za injiciranje palifermin
Kepivance is a powder that is made up into a solution for injection.
prašek za raztopino za injiciranje (prašek za injekcijo) bel liofiliziran prašek
Kepivance is a white powder supplied in vials.
Zdravilo Kepivance je bel prašek v vialah.
Kepivance is used to decrease the frequency, duration and severity of oral mucositis (inflammation of the lining of the mouth, ranging from soreness and redness to severe ulceration).
Učinki so bili predvsem blagi do zmerni in so bili reverzibilni.
Kepivance should be reconstituted with 1.2 ml water for injections.
Zdravilo Kepivance pripravite z 1,2 ml vode za injekcije.
Kepivance should not be administered if discolouration or particulates are observed.
Če opazite obarvanje ali delce, zdravila Kepivance ne smete uporabiti.
Kepivance should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of cytotoxic chemotherapy.
Zdravila Kepivance ne smete uporabiti v 24 urah pred, med ali v 24 urah po apliciranju citotoksične kemoterapije.
Kepivance should not be used during pregnancy unless clearly necessary.
Zdravila Kepivance med nosečnostjo ne smete uporabljati, razen če je nujno potrebno.
Kepivance treatment should be supervised by a physician experienced in the use of anti-cancer therapy.
Zdravljenje z zdravilom Kepivance lahko izvaja samo zdravnik z izkušnjami pri zdravljenju raka.
Keppra 100 mg/ml concentrate for solution for infusion
Keppra 100 mg/ml koncentrat za raztopino za infundiranje
Keppra 100 mg/ml only for the outer carton
Keppra 100 mg/ml samo za zunanjo ovojnino
Keppra 100 mg/ml oral solution
Keppra 100 mg/ml peroralna raztopina
Keppra 100 mg/ml oral solution is a clear liquid.
Zdravilo Keppra 100 mg/ml peroralna raztopina je bistra tekočina.
Keppra 1000 mg film-coated tablets
Keppra 1000 mg filmsko obložene tablete
Keppra 250 mg film-coated tablets
Keppra 250 mg filmsko obložene tablete
Keppra 250 mg film-coated tablets are blue, 13 mm oblong, scored and debossed with the code “ucb” and “250” on one side.
Zdravilo Keppra 250 mg filmsko obložene tablete so modre, 13 mm podolgovate, z zarezo in imajo na eni strani vtisnjeni oznaki »ucb« in »250«.
Keppra 250 mg film-coated tablets Keppra 500 mg film-coated tablets Keppra 750 mg film-coated tablets Keppra 1000 mg film-coated tablets Levetiracetam
Keppra 250 mg filmsko obložene tablete Keppra 500 mg filmsko obložene tablete Keppra 750 mg filmsko obložene tablete Keppra 1000 mg filmsko obložene tablete levetiracetam
Keppra 500 mg film-coated tablets
Keppra 500 mg filmsko obložene tablete
Keppra 750 mg film-coated tablets
Keppra 750 mg filmsko obložene tablete
Keppra 750 mg film-coated tablets contain E110 colouring agent which may cause allergic reactions.
Zdravilo Keppra 750 mg filmsko obložene tablete vsebuje barvilo E110, ki lahko povzroči alergijske reakcije.
Keppra 750 mg tablets contain Sunset Yellow FCF (E110).
Zdravilo Keppra 750 mg tablete vsebuje barvilo sončno rumeno FCF (E110)
Keppra concentrate for solution for infusion (sterile concentrate) is a clear, colourless liquid.
Keppra koncentrat za raztopino za infundiranje (sterilni koncentrat) je bistra, brezbarvna tekočina.
Keppra concentrate is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15-minute intravenous infusion (see section 6.6).
Koncentrat zdravila Keppra je samo za intravensko uporabo, priporočeni odmerek mora biti razredčen v vsaj 100 ml kompatibilnega topila in uporabljen intravensko kot 15-minutna intravenska infuzija (glejte poglavje 6.6).
Keppra has also been compared with placebo in 314 patients aged between one month and 17 years; in myoclonic seizures, Keppra was studied in 122 patients aged 12 years and over, who received either Keppra or placebo in addition to their normal anti-epileptic medicine for up to 30 weeks; in primary generalised tonic-clonic seizures, Keppra was compared with placebo in 164 patients aged four years or over.
Zdravilo Keppra so primerjali tudi s placebom pri 314 bolnikih, starih od enega meseca do 17 let; pri miokloničnih napadih, in sicer pri 122 bolnikih, starih 12 let in več, ki so do 30 tednov poleg svojega običajnega zdravila proti epilepsiji prejemali zdravilo Keppra ali placebo; pri primarno generaliziranih tonično-kloničnih napadih, pri katerih so zdravilo Keppra primerjali s placebom pri 164 bolnikih, starih štiri leta in več.
Keppra has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures.
Študije na živalih so pri odmerkih zdravila Keppra, ki so višji kot je potrebno za nadzor napadov, pokazale neželene učinke na razmnoževanje.
Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Zdravilo Keppra je indicirano za samostojno zdravljenje parcialnih napadov izvora s sekundarno generalizacijo ali brez nje pri odraslih in mladostnikih od 16. leta starosti z na novo diagnosticirano epilepsijo.
Keppra is not indicated in children and adolescents below 16 years on its own (monotherapy).
zdravilo Keppra, pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija).
Keppra is not indicated in children and adolescents below 16 years on it’s own (monotherapy)
zdravilo Keppra, pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija)
Keppra is not indicated in children and adolescents below 16 years on it’s own (monotherapy)
zdravilo Keppra, pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija).
Keppra is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.
Zdravila Keppra med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije, ni priporočljivo uporabljati, razen če ni klinično potrebno.
Keppra is used as a chronic treatment.
Zdravilo Keppra se uporablja za dolgotrajno zdravljenje.
Keppra may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy.
Zdravilo Keppra lahko oslabi vašo sposobnost vožnje ali upravljanja z orodjem ali stroji, saj lahko Keppra povzroči zaspanosti.
Keppra oral solution is the preferred formulation for use in infants and children under the age of 6 years.
Pri dojenčkih in otrocih, mlajših od 6 let je najprimernejša farmacevtska oblika za uporabo zdravilo Keppra peroralna raztopina.
Keppra oral solution may be diluted in a glass of water or baby’s bottle.
Peroralno raztopino zdravila Keppra lahko razredčite v kozarcu vode ali v steklenici za hranjenje otrok.
Keppra should not be used during pregnancy unless clearly necessary.
Zdravila Keppra med nosečnostjo ne smete uporabljati, razen kadar je nedvomno potrebno.
Keppra was also more effective than placebo in children; for myoclonic seizures, the number of seizure days per week was halved in 58% of the patients receiving Keppra and in 23% of the patients receiving placebo; for tonic-clonic seizures, the number of seizures fell by an average of 28% in the patients receiving placebo, compared with 57% in those receiving Keppra.
Zdravilo Keppra je bilo učinkovitejše od placeba tudi pri otrocih; pri miokloničnih napadih, pri katerih se je število dni z napadi na teden prepolovilo pri 58 % bolnikov, ki so prejemali zdravilo Keppra, in 23 % bolnikov, ki so prejemali placebo; pri tonično-kloničnih napadih, pri katerih se je število napadov v povprečju zmanjšalo za 28 % pri bolnikih, ki so jemali placebo, v primerjavi s 57 % pri bolnikih, ki so jemali zdravilo Keppra.
kept in mind that a twice weekly dose of 150 mg may not provide an optimal exposure to rifabutin thus leading to a risk of rifamycin resistance and a treatment failure.
Vedeti je treba, da morda odmerek 150 mg dvakrat tedensko ne zagotavlja optimalne izpostavljenosti rifabutinu, kar ima lahko za posledico rezistenco na rifamicin in neuspeh zdravljenja.
Keratitis (0.12%)
Keratitis (0,12 %)
keratitis (inflammation of the front part of the eye (cornea)); eyelid irritation; chapped lips and/or dry lips; eye infection; eyelid infection; nasal dryness; loosening of the nails (onycholysis); ingrowing nail; excessive hair growth (hirsutism);
keratitis (vnetje sprednjega dela očesa (roženice)), draženje vek, razpokane ustnice in/ali suhe ustnice, okužba oči, okužba vek, suhost nosu, odstopanje nohtov (oniholiza), vraščanje nohta, čezmerna rast dlak (hirzutizem).
Keratitis bacterial, herpes zoster ophthalmic.
bakterijski keratitis, očesni herpes zoster
Keratitis herpetic
herpetični keratitis